MoneyWorks4Me

Lupin launches authorized generic version of Ravicti in United States

24 Oct 2025 Evaluate

Lupin has launched an authorized generic version of Ravicti (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL is indicated for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2190.00 -3.00 (-0.14%)
24-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1909.90
Dr. Reddys Labs. 1194.50
Cipla 1435.00
Lupin 2190.00
Zydus Lifesciences 1101.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: